2-[1-[[(1R)-3-[2-(2-hydroxypropan-2-yl)phenyl]-1-[3-[(E)-2-(7-methylquinolin-2-yl)ethenyl]phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 2-[1-[[(1R)-3-[2-(2-hydroxypropan-2-yl)phenyl]-1-[3-[(E)-2-(7-methylquinolin-2-yl)ethenyl]phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
• 化学式: C₃₆H₃₉NO₃S
• 分子量: 565.8
• InChiKey: GUIADMSPJAYZIW-PWXLVQELSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  41
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  95.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION
  申请人：OSAKA UNIVERSITY

  公开号：US20140220059A1

  公开（公告）日：2014-08-07

  The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.
• WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION
  申请人：OSAKA UNIVERSITY

  公开号：US20140220057A1

  公开（公告）日：2014-08-07

  The present invention provides a cancer vaccine composition for transdermal administration for cellular immunity induction, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a pharmacologically acceptable acid as a first cellular immunity induction promoter, or a pharmacologically acceptable salt thereof.
• VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION
  申请人：NITTO DENKO CORPORATION

  公开号：US20140220079A1

  公开（公告）日：2014-08-07

  The present invention provides a cancer vaccine composition for mucosal administration comprising (i) a HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide; and (ii) a first cellular immunity induction promoter.
• METHODS OF TREATING OR PREVENTING VASCULAR DISEASES OF THE RETINA
  申请人：Children's Medical Center Corporation

  公开号：US20160339008A1

  公开（公告）日：2016-11-24

  The present invention features, in part, methods of treating or preventing vascular diseases of the retina in a subject, methods of treating or preventing angiogenesis in a subject and methods of treating or preventing neovascularization in a subject comprising administering to a subject a therapeutically effective amount of an inhibitor of cytochrome P450 2C8 (CYP2C8) activity or expression, or a promoter of sEH activity or expression.
• [EN] BILAYER TABLET FORMULATIONS OF MONTELUKAST AND RUPATADINE<br/>[FR] FORMULATIONS DE COMPRIMÉ BICOUCHE DE MONTÉLUKAST ET DE RUPATADINE
  申请人：SANOVEL ILAC SANAYI VE TICARET AS

  公开号：WO2017182641A1

  公开（公告）日：2017-10-26

  The present invention relates to a bilayer tablet formulation comprising montelukast sodium and rupatadine fumarate.